Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Arnold A, Imada EL, M Zhang L, Edward DP, Marchionni L, Rodriguez FJ. Correction to: Differential gene methylation and expression of HOX transcription factor family in orbitofacial neurofibroma. Acta Neuropathol Commun. 2020;8(1):69.

Entenberg D, Oktay MH, D'Alfonso T, Ginter PS, Robinson BD, Xue X, et al. Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for Metastasis. Cancers (Basel). 2020;12(4).

Manur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, et al. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/-rearranged myeloid/lymphoid neoplasm with mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leuk Lymphoma. 2020;61(2):450-454.

Saqi A, Mukhopadhyay S, Butt Y, Doxtader E, Heymann JJ, Larsen BT, et al. E-cigarette or vaping product use-associated lung injury: What is the role of cytologic assessment? Cancer Cytopathol. 2020;128(6):371-380.

Li S, Kendall J, Park S, Wang Z, Alexander J, Moffitt A, et al. Copolymerization of single-cell nucleic acids into balls of acrylamide gel. Genome Res. 2020;30(1):49-61.

Marzio A, Pagano M. Loss of the deubiquitinase OTULIN promotes hepatocellular carcinoma (HCC) in an mTOR-dependent manner. Cell Death Differ. 2020;27(5):1455-1456.

Patel SS, Lipschitz M, Pinkus GS, Weirather JL, Pozdnyakova O, Mason EF, et al. Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Mod Pathol. 2020;33(7):1380-1388.

Bagheri S, Pantrangi M, Sodhi SK, Bagheri S, Oellers P, Scholl HP. A NOVEL LARGE HOMOZYGOUS DELETION IN THE CELLULAR RETINALDEHYDE-BINDING PROTEIN GENE (RLBP1) IN A PATIENT WITH RETINITIS PUNCTATA ALBESCENS. Retin Cases Brief Rep. 2020;14(1):85-89.

Moscat J, Diaz-Meco MT. The interplay between PRKCI/PKCλ/ι, SQSTM1/p62, and autophagy orchestrates the oxidative metabolic response that drives liver cancer. Autophagy. 2020;16(10):1915-1917.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.